|
US2015238490A1
|
|
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
|
US2015152115A1
|
|
Inhibitors of bruton's tyrosine kinase
|
|
WO2015073833A1
|
|
Methods for delaying or preventing the onset of type 1 diabetes
|
|
CN105848680A
|
|
Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
|
|
WO2015017812A1
|
|
Methods for the treatment of solid tumors
|
|
WO2014130693A1
|
|
Inhibitors of bruton's tyrosine kinase
|
|
CA2890934A1
|
|
Pyrrolopyrimidine compounds as kinase inhibitors
|
|
SG11201503459SA
|
|
Tec family kinase inhibitor adjuvant therapy
|
|
MX2015004576A
|
|
Companion diagnostics for tec family kinase inhibitor therapy.
|
|
KR20150032340A
|
|
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
WO2013173518A1
|
|
Inhibitors of bruton's tyrosine kinase
|
|
MX2014009892A
|
|
Combinations of histone deacetylase inhibitor and pazopanib and uses thereof.
|
|
WO2013101600A1
|
|
Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
|
|
CN110801454A
|
|
Use of Bruton's Tyrosine Kinase (BTK) inhibitors
|
|
US2014080879A1
|
|
Factor VIIa inhibitor
|
|
JP2013014602A
|
|
High-purity texaphyrin metal complex
|
|
MX2014000518A
|
|
Inhibitors of bruton's tyrosine kinase.
|
|
US8377946B1
|
|
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
SG10201607620YA
|
|
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
|
AU2011261185A1
|
|
The use of inhibitors of Bruton's tyrosine kinase (Btk)
|
